Dow Jones
38.016,99 -369,10 (-0,96%) Nasdaq
15.807,62 -175,46 (-1,10%) Nikkei 225
38.405,66 +470,90 (+1,24%) EUR/USD
1,0679 -0,0046 (-0,43%) Bitcoin EUR
58.726,11 -631,68 (-1,06%) CMC Crypto 200
1.291,50 -47,57 (-3,55%)
ORIC Pharmaceuticals Inc (4TZ.BE)
| Chiusura precedente | 7,70 |
| Aperto | 7,65 |
| Denaro | 8,30 x N/D |
| Lettera | 8,60 x N/D |
| Min-Max giorno | 7,60 - 8,35 |
| Intervallo di 52 settimane | 4,50 - 14,90 |
| Volume | |
| Media Volume | 5 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | N/D |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | 06 mag 2024 - 10 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswireORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 06, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 2, 2023 (the “Grant Date”), ORIC granted a total of 72,120 non-qualified stock options and 12,040 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2023. These inducement g
- GlobeNewswire
ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 8:00 a.m. ET. A live webcast of the discussion will be available through the investor section of the company’
- GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO and SAN DIEGO, Aug. 30, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September: Citi’s 2023 18th Annual BioPharma Conference – Participating in a targeted oncology panel on Wednesday, September 6, 2023, at 1:00 p.m. ET Wells Fargo
